Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 22, 2022 - Issue 2
Submit an article Journal homepage
1,675
Views
8
CrossRef citations to date
0
Altmetric
Meta-analysis

Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis

Farah Latifa Research and Publications, Fatima Jinnah Medical University, Lahore, PakistanView further author information
,
Hira Bint Abdul Jabbarb Research, King Edward Medical University, Lahore, PakistanView further author information
,
Hamna Malikc Research, Services Institute of Medical Sciences, Lahore, PakistanView further author information
,
Humaira Sadafd Internal Medicine, University of Texas Health Science Centers, McGovern Medical School, Houston, Texas, USAView further author information
,
Azza Sarfraze Pediatrics and Child Health, The Aga Khan University, Karachi, PakistanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8206-5745View further author information
ORCID Icon,
Zouina Sarfraza Research and Publications, Fatima Jinnah Medical University, Lahore, PakistanORCID Iconhttps://orcid.org/0000-0002-5132-7455View further author information
ORCID Icon &
Ivan Cherrez-Ojedaf Allergy and Pulmonology, Universidad Espíritu Santo, EcuadorORCID Iconhttps://orcid.org/0000-0002-1610-239XView further author information
ORCID Icon show all
Pages 229-235 | Received 28 May 2021, Accepted 21 Dec 2021, Published online: 24 Jan 2022

References

  • Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Vol. 22. New York, USA: Oncology (Williston Park); 2008. p. 1233–1243.
  • Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010;16(1):53–61.
  • Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol. 2014;193(8):3835–3841.
  • Grossman JE, Vasudevan D, Joyce CE, et al. Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor. Oncogene. 2021;40(8):1393–1395.
  • Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.
  • Lipson EJ, Forde PM, Hammers H-J, et al. Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol. 2015 Jun 10;42(4):587–600.
  • FDA. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer (USA). 2019.
  • FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast cancer. [cited 2021 Sep 1]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-locally-recurrent-unresectable-or-metastatic-triple
  • Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372(160):1–75.
  • Miles D, Andre F, Gligorov J, et al. IMpassion131: phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC). Ann Oncol. 2017;28:105.
  • Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121.
  • Palleschi M, Maltoni R, Sarti S, et al. Immunotherapy: the end of the “dark age” for metastatic triple-negative breast cancer? Breast J. 2020;26(4):739–742.
  • Cerbelli B, Pernazza A, Botticelli A, et al. PD-L1 expression in TNBC: a predictive biomarker of response to neoadjuvant chemotherapy? Gasparri ML, editor. Biomed Res Int. 2017; 2017:1750925.
  • Budczies J, Bockmayr M, Denkert C, et al. Classical pathology and mutational load of breast cancer – integration of two worlds. J Pathol Clin Res. 2015;1(4):225–238.
  • Beckers RK, Selinger CI, Vilain R, et al. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology. 2016;69(1):25–34.
  • Adams S, Diéras V, Barrios CH, et al. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020;31(5):582–589.
  • Zong Y, Pegram M. Research advances and new challenges in overcoming triple-negative breast cancer. Cancer Drug Resist. 2021;4.
  • Guo H, Ding Q, Gong Y, et al. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. Breast Cancer Res. 2020;22(1):69.
  • Conroy JM, Pabla S, Nesline MK, et al. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):18.
  • Kwa MJ, Adams S. Checkpoint inhibitors in triple-negative breast cancer (TNBC): where to go from here. Cancer. 2018;124(10):2086–2103.
  • Leite KRM, Barrios CH, Buzaid AC, et al. Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil. Surg Exp Pathol. 2021;4(1):10.
  • Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620.
  • Lyman GH, Burstein HJ, Buzdar AU, et al. Making genuine progress against metastatic breast cancer. J Clin Oncol. 2012;30(28):3448–3451.
  • Keenan TE TS, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020;18(4):479–489.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.